Volume 4, Issue 1, March 2019, Page: 13-17
A Review of Contemporary Markers of Insulin Resistance
Ekpe Lawson, Department of Chemical Pathology, University of Calabar, Calabar, Nigeria
Onuche Lawrence, Department of Chemical Pathology, University of Calabar Teaching Hospital, Calabar, Nigeria
Received: Nov. 29, 2018;       Accepted: Jan. 2, 2019;       Published: Feb. 19, 2019
DOI: 10.11648/j.ijde.20190401.13      View  106      Downloads  17
Abstract
Backgrounnd: The era of non-communicable diseases has been here with us for a while. Diabetes mellitus, pre-diabetes, insulin resistance, metabolic syndrome and associated complications; have been the centre of interest for many researchers lately. Insulin resistance (IR) has taken a forefront position in this regard. Aim: Insulin resistance has been implicated in the pathogenesis of many metabolic disorders. It heralds the onset of many of these diseases many years before the clinical signs and symptoms. Method: A thorough literature search was done using internet academic search engines and indexation such Google scholar, hinari, Ebsco, Scorpus, etc. Results: Insulin resistance (IR), an independent risk factor for the development of Type 2 diabetes and metabolic syndrome is assessed by several biomarkers. From the historical perspective till date, the authors assess the implication, connection and relevance from various studies to contemporary scientific breakthroughs in this regard for diagnosis and clinical application of markers of insulin resistance in patient management. Conclusion: It is hoped that with the advancement in medical research, more markers of insulin resistance will be discovered that will help in patient managements.
Keywords
Insulin Resistance, Markers, Diabetes, Metabolic Syndrome, Diseases
To cite this article
Ekpe Lawson, Onuche Lawrence, A Review of Contemporary Markers of Insulin Resistance, International Journal of Diabetes and Endocrinology. Vol. 4, No. 1, 2019, pp. 13-17. doi: 10.11648/j.ijde.20190401.13
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Borad A. Assessing insulin resistance: Clinical laboratory news of AACC. August 2016.
[2]
Insulin resistance. In: www.wikipedia.com/insuilin resistance.
[3]
Mohammed Al-far, Mohammed IM. Biochemical study of the effects of IR on sex hormones in men and women type 2 diabetic patients: Advances in Biochemistry 2017 S (5): 79 – 88.
[4]
Sneha S, Rao S, Vidyasagar S. Anthropometric and Biochemical markers of insulin resistance. International Journal of Science and Research. 2016: 442 – 924.
[5]
Kipres MS, Kronick A, Rendell MS, Egan JW, Mathisen AL. Pioglitazone hydrochloride in combination with Sulphonyurea therapy improves glycemic control in patients with type 2 diabetic mellitus. A randomized placebo-controlled study. Am J. Med. 111:10 – 17, 2007.
[6]
Singh, B, Sexena A. Surrogate marker, of insulin resistance: A review World Journal of Diabetes: 15:1 (2):36-47, 2010.
[7]
Reaven GM, Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1593 – 1607, 1988.
[8]
Muniyappa R, Lee S, Chou H, Quon MJ Current approaches for assessing insulin sensitivity and resistance in viro: advantages, limitations and appropriate usage. Am J physical Endocrinol Metab. 2008; 294 (1) E 15 – 26.
[9]
Harrigan RA, Nathan MS, Beattle P. Oral agents for the treatment of type 2 diabetes mellitus: Pharmacology, toxicity, and treatment. Annals of Emergency Medicine 2001.38 (1): 68-78.
[10]
Reaven GM. The insulin resistance syndrome: Definition and dietary approaches to treatment. Annu Rev. Natl. 25: 391-406, 2005.
[11]
Defranzo. RA, Ferranini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, Hypertension, dyslipidemia and atherosclerotic cardiovascular disease.
[12]
Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S. E. 2007. Inaugural lecture article: The role of skeletal muscle IR in the pathogenesis of the metabolic syndrome. Proct Natl Acad Sci, USA. 104: 12587 – 12594, 1997.
[13]
Borai A, Livingstook C, Ferns GA. The biochemical assessment of insulin resistance. Annals of Cinical Biochemistry 2007; 44: 324–342.
[14]
Krauss RM. Lipids and Lipoproteins in Patients With Type 2 Diabetes Diabetes care 2007; 44; 314 – 342.
[15]
Greave J. Inhibition of the synthesis of apolipoprotein B containing lipoprotein. Hand Exp Pharmacol 2005; 170: 483 – 617.
[16]
Lee JM Choudlury RP. Prospects for atherosclerosis regression: HDL elevation and other emerging therapeutic technologies. Heart: 2007, 93: 559 – 64.
[17]
Marakmaan P, Dietary treatment of thrombogenic disorders related to the metabolic syndrome. Br J Nutr 2000; 83 (Supp 1): S 121 – 6.
[18]
Kahn BB, Flier JS. Obesity and insulin resistance The Journal of Clinical Investigations 2001: 7412: 1108 – 16.
[19]
Ginsberg HN. Insulin Resistance and Cardiovascular disease. J. Clin. Invest. 2000, 106: 453 – 8.
[20]
Lillioja S, Moh DM, Howard BV, BemoHpH. Impaired glucose tolerance as a disorder of insulin action: longitudinal cross sectional studies in Pima Indians. N Engl Med. 1988. 318 (19): 1217 – 1228.
[21]
Wills, J, Watson JM, Hales CN, Phillips DI. The relation of fetal growth to insulin secretion in young men. Diabet Med 1996; 13: 773 – 4.
[22]
Haring H, Obermaier B, Ermel B, et al. Insulin receptor kinase defects as a possible cause of cellular insulin resistance. Diabetes Metab 1987; 13:284 – 93.
[23]
Innes, KE, Wimsatt JH. Pregnancy-induced hypertension and insulin resistance: evidence for a connection. Acta Obstet Gynecol 1999; 78:263 – 84.
[24]
Maron DJ, Fair JM, Haskell WL. Saturated fat intake and insulin resistance in men with coronary artery disease. The Standford Coronary Risk Intervention project investigations and stuff. Circulation 1991: 84: 2020 – 7.
[25]
Gustat J, Elkasabany A. Srinivasan S, Berenson GS. Relation of self-rated measures of physical activity to multiple risk factor insulin resistance syndrome in young adults: The Bogulusu heart study. J. Clin. Epidemiol 2002; 55: 997 – 1006.
[26]
Kernielli E, Cohem P, Barzilai N. et al. Insulin resistance in Cushings syndrome. Horm. Metab Res 1985: 17: 518 – 21.
[27]
Raza SA, Dewitt RT, Chan H, Warner TF, Blank RD. Catecholamine excess in phaecromocytoma inducing insulin resistance. Endocr Pract 2004: 149 – 52.
[28]
Apridonidze T, Essah PA, Iwomo MJ, Nestler JE, Prevalence and characteristic of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol Metab.2005; 90: 1929 – 35.
[29]
Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J. Med 1987; 317: 350 – 7.
[30]
Sam S. Obesity and Polycystic ovary Syndrome. Obes Manag 2007; 3 (2):69-73.
[31]
Rojas J, Chavez M, Olivar L, Rojas M, Morillo J. Insulin resistance and obesity: Navigating the pathophysiologic labyrinth Int J Reprod Med 2014:719050.
[32]
Dunaif A. Insulin resistance and the polycystic ovary system. mechanism and implications for pathogenesis. Endocr Rev 1997; 18 (6):774-800.
[33]
Romo A, Benavides S. Acanthosis nigricans associated with insulin resistance: Pathophysiology and management. Am J Clin Dermatol. 2004; 5:199–203.
[34]
Hermans – Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: Pathophysiology and management. Am J Clin. Dermatol 2004; 5 (3): 199 – 203.
[35]
Jaquest D, Tregouet DA, Nicacud V, Godefroy T. Combined effects of genetic and environmental factors on insulin resistance associated with reduced fetal growth. Diabetes 2002; 51 (12): 3473 – 3478.
[36]
Kahn R. Weight gain and insulin therapy. British Journal of Diabetes and Vascular Disease. 2004; 4 (4): 264-267.
[37]
Eckel RH. Lipoprotrin lipase A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med. 1989, 320: 1060 – 1068.
[38]
Reinehr T, Andler W. Cortisol and its relation to insulin resistance before and after weight loss in obese children. Horn Res. 2004; 62 (4): 107 – 12.
[39]
Aronoff, SL, Berkowitz K, Shreiner Barb, Want L Glucose Metabolism and Regulation: Beyond Insulin and Glucagon.. Diabetes Spectrum 2004 Jul; 17 (3): 183-190.
[40]
Defronzo RA, Bonadonna RC, Ferrannimi E. Pathogenesis of NIDDM: A balanced view – Diabetes Care. 1992; 151; 318 – 368.
[41]
Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with insulin suppression test and the euglycemic clamp. Diabetes 1981: 30 (5): 387 – 92.
[42]
Matthew Dr, Hosker JP, Rudenski AS, Naylor BA, Turner RC. Homeostastic model assessment. Insulin resistance and beta cell function from fasty plasma, glucose and insulin concentration in man. Diabetologic 1985, 28: 412 – 419.
[43]
Arora S. Surrogate markers of insulin resistance: A review. World Journal of Diabetes. 2010: 15 (2) 36 – 47.
[44]
Duncan MH, Singh BM, Wise PH, Carter G. A simple measure of insulin resistance. Lancet 1955, 346: 720 – 121.
[45]
Matthew KJ, Hunt AE, Steinberg HO, Paradisi, G. Repeatedly characteristic of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001, 86: 5457 – 5464.
[46]
Sneha S, Sudhaker R, Vidyasugar Anthropometric and Biochemical markers of insulin resistance: IJSR 2013, 922 – 923.
[47]
Hsieh CH, Kuo SW, Hung XJ, Shen DC HO CT. metabolic characteristics in individuals with impaired glucose homeostasis. Int. J. Clin. Pract. 2005; 59:639 – 644.
[48]
Levine R, Haft DE, Carbohydrate Homeostasis. N Eng J Med 1970: 283: 287 – 246.
[49]
Myllnen P, Koivisto VA, Nikkila EA. Glucose intolerance and insulin resistance accompany immobilization. Acta Med Scand 1987, 222: 75 – 81.
[50]
Bergman RN, Ider YZ, Bowden CR, Cobelli, Quantitative estimation of insulin sensitivity.
[51]
Consensus Development conference on insulin resistance. November 1997. American Diabetes Association. Diabetes Care. 1998. 21: 310 – 314.
[52]
Mari, A, Pacini G, Murphy E, Ludrik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the cool glucose tolerance test. Diabetes Care. 2001, 24: 539 – 548.
[53]
Goedecke JH, Dare JA, Faulenbaeh MV. Insulin response in relation to insulin sensitivity: an appropriate beta – cell response in black South African women. Diabetes Care 200, 32: 360 – 865.
[54]
Osei K, Rhinesmith S, Gaillerd T, Schuster D. Is glycosylated haemoglobin AIC a surrogate for metabolic syndrome in non diabetic, first degree relation of African – American patient with type 2 diabetes. Clin Exdocrinol Metab 2003, 88: 4596 – 4601.
[55]
Hivert MF, Sullivan IM, Fox CS, Nathan DM. association of adiponection, resisting and tumor necrosis factor alpha with insulin resistance. J Clin Endorinol Metab 2004; 89: 87 – 90.
[56]
Kajaia N, Binder H, Diitrieh R, Oppelt PG, Flor B, Cupisti S, Low Sex hormone binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. Eur J Endocrinol 2007:157:499 – 507.
[57]
Higashiura K, Ura N, Ohata J, Togashi N Takagi S. Correlation of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol 2004, 61: 753 – 759.
[58]
John M, Clark JM, Gundlar E. Serum ferritin and risk of the metabolic syndrome on US adults. Diabetes Care 2004: 27: 2422 – 2428.
[59]
Pham NM, Nanri A, Kurotani K, Akter S, Foo LH, Nishi N. Serum ferritin is associated with markers of insulin resistance in Japanese men but not in women. Metabolism 2013.6 (24):561-7
[60]
Meng YX, Ford ES, Li C, Quarshe A. Al-Mahmoud AM, Giles W. Association of C – reactive proteins with surrogate measures of insulin resistance among non-diabetics from US from National Health and Nutrition Examination Survey. 1999 – 2002, Clin Chem 2007, 53: 2152 – 2159.
[61]
Cordero A, Alegria- Ezquerrra E. TG/HDL ratio as surrogate marker for insulin resistance ESC Council for Cardiology Practice 2009, 8 (16).
[62]
Motaghadi R, Guijral S, Sinha S, Sison C, Ten S, Macleran NK. Insulin-like growth factor binding protein to screen for insulin resistance in children. Diabetes Technol Thor 2007, 9: 43 – 51.
[63]
Glueck CJ, Khan NA, Umar Mohammad, Uppal MS, Ahmed W. Insulin resistance and triglycerides. Journal of Investigative Medicine 2009; 57: 874-881.
[64]
Zinman B, hanley AJ, harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor alpha concentration in a native Canadaian population with high rates of type 2 diabetes in older men and women: The hoorn study. J Clin Endocrinol Metab 1999; 84:272-278
[65]
Handberg A, Levin K, Hojlund K. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation 2006; 114: 1169 – 1176.
[66]
Muscari A, Antonelli S, Bianchi G, Cavrini G, Dapparto S, Ligabue. Serum C3 is a stronger inflammatory marker of insulin resistance than C – reactive protein leucocyte, and erythrocyte sedimentary rate: Comparison study in an elderly population. Diabetes Care, 2007: 30: 2362 – 2368.
[67]
Muniyappa R, Lee S, Chen H, Quon MJ (January 2008). "Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage". American Journal of Physiology. Endocrinology and Metabolism. 294 (1): E15–26.
[68]
Friedman JM (April 2000). "Obesity in the new millennium". Nature. 404 (6778): 632–4.
[69]
Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM (July 1995). "Weight-reducing effects of the plasma protein encoded by the obese gene". Science. 269 (5223): 543–6.
Browse journals by subject